Song J, et al. - Researchers analyzed data from studies comparing the efficacy of bevacizumab (BEV) in addition to lomustine (CCNU) vs single-agent therapy in patients with recurrent glioblastoma (GBM), focusing mainly on progression-free survival (PFS) and overall survival (OS). These studies were identified through a search of electronic databases. They used RevMan software to pool all the data with corresponding 95% confidence intervals (CIs). Quantitative analysis of sensitivity and heterogeneity was also carried out. Overall, the analysis included 3 randomized clinical trials, including 574 patients (combination group: 358, monotherapies group: 216). Findings revealed prolonged PFS resulting from treatment with CCNU plus BEV, but when compared with monotherapies in patients with progressive GBM, it failed to confer better OS advantage.